Alnylam Rare Disease Trend Report Sixth Edition

The Alnylam Rare Disease Trend Report, sixth edition, presents insights from payers and employer stakeholders regarding the management of rare diseases and specialty therapies. It outlines the challenges associated with the development and reimbursement of rare disease therapies, emphasizing the balance between innovation, affordability, and access. The report notes that orphan drugs represent a significant portion of new molecular entities, despite the financial pressures faced by payers due to rising drug costs and policy changes like the Medicare Part D Redesign. The report aims to enhance understanding of these trends by addressing key questions about stakeholder priorities, the impact of financial pressures on benefit design, and the influence of policy changes on strategies for managing rare disease therapies. Additionally, it discusses the role of innovative technologies in improving operational efficiencies. This edition integrates perspectives from both payers and employers, reflecting the evolving landscape of rare disease management.